Molibresib besylate (GSK525762C) is a potent and selective BET bromodomain inhibitor studied for refractory hematologic cancers. It induces reactive oxygen species (ROS) and ATM activation, demonstrating antitumor activity in both in vitro and in vivo preclinical models.